BCLI Stock UPDATES Brainstorm Cell Ther (BCLI) 0.2975 08/19/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Brainstorm Cell Ther (BCLI) 0.2975 $BCLI

FDA Clears Mayo Clinic for Manufacture of NurOwn and Participation in BrainStorm's Phase 2 ALS Trial
ACCESSWIRE - Mon Aug 18, 7:13AM CDT
NEW YORK, NY and PETACH TIKVAH, Israel /ACCESSWIRE / August 18, 2014 / BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Mayo Clinic Human Cellular Therapy Laboratory in Rochester, Minn. for production of NurOwn™, BrainStorm's proprietary autologous mesenchymal stem cells secreting neurotrophic factors (MSC-NTF). BrainStorm will continue working with the Mayo clinical team to complete the necessary steps to allow the site to begin enrolling subjects into its ongoing phase 2 study of NurOwn™, which is designed to evaluate the safety and efficacy of the transplantation of or NurOwn™ in patients with Amyotrophic Lateral Sclerosis (ALS).

BrainStorm Receives Notice of Allowance on US Patent
ACCESSWIRE - Mon Jul 28, 8:47AM CDT
NEW YORK, NY and PETACH TIKVAH, Israel / ACCESSWIRE / July 28, 2014 / BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, received Notice of Allowance from the United States Patent Office for Patent Application 12/994,761, titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."

BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical Trial
eTeligis - Tue Jul 15, 10:04AM CDT
Petach Tikvah, Israel, New York, NY, United States, via eTeligis Inc., 07/15/2014 - - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the University of Massachusetts (UMass) Memorial Medical Center in Worcester, MA will begin enrolling patients into the Company's randomized, double-bling placebo-controlled phase 2 clinical trial in Amyotrophic Lateral Sclerosis (ALS). UMass Memorial is the second site to become active of the three sites participating in this trial. The other two clinical sites participating in the multi-center trial are Massachusetts General Hospital (MGH), which began enrolling patients into the trial last month, and the Mayo Clinic, which is expected to become active in the third quarter of 2014. The Dana Farber Cancer Institute's Connell and O'Reilly Cell Manipulation Core Facility will manufacture NurOwn cells for MGH and UMass Memorial.

BrainStorm publishes study of preclinical multidose in mice of NurOwn
M2 - Fri Jul 11, 7:01AM CDT
Adult stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLI) announced on Friday that it has published a preclinical study about the safety of single and repeated intramuscular administration of NurOwn, its proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors, in the Clinical and Translational Medicine journal.

BrainStorm Announces Publication of Preclinical Multidose Study of NurOwn
Marketwire - Fri Jul 11, 6:08AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today publication of an important preclinical study in the journal Clinical and Translational Medicine. This paper describes the safety of single and repeated intramuscular administration of NurOwn, the Company's proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors. NurOwn is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and has demonstrated efficacy in preclinical models of a variety of neurodegenerative diseases, including Parkinson's disease, Huntingon's disease and multiple sclerosis. The results published today are important because they establish that repeated doses of NurOwn are safe in mice and more specifically, that mice generate only minimal immune response after repeated exposure to NurOwn, which are human cells. These data will help support the use of multiple doses of NurOwn in future clinical trials.

OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell Therapeutics, Inc., Advanced Cell Technology, Inc.
PR Newswire Europe - Tue Jul 01, 7:01AM CDT
LONDON, July 1, 2014 /PRNewswire/ --

BrainStorm and Octane Successfully Construct a Bioreactor Prototype for Industrial-Scale Manufacturing or NurOwn Stem Cells
Marketwire - Fri Jun 27, 8:50AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian firm that focuses on clinical systems for cell and tissue therapy, announced today that they have reached an important milestone in their technology collaboration, successfully constructing an Alpha prototype of a customized bioreactor for BrainStorm's NurOwn(TM) neurotrophic-factor secreting mesenchymal stem cells. The proprietary bioreactor under development will provide BrainStorm with large-scale manufacturing capabilities, enabling it to achieve economies of scale for its autologous stem cell product.

BrainStorm Cell Therapeutics Raises $10.5 Million in Private Placement Financing
Marketwire - Fri Jun 13, 8:30AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System therapeutics, today announced that it has entered into definitive agreements with a group of investors, including several healthcare-focused funds, in connection with a private placement of common stock and warrants to purchase common stock. Upon the closing of this financing, BrainStorm will receive gross proceeds of $10.5 million, resulting from the issuance and sale of 42.0 million shares of common stock at a price per share of $0.25, a 15% discount to the 30 day volume-weighted average price of $0.294. The purchasers will also receive warrants to purchase up to 42.0 million shares of common stock at an exercise price of $0.348 per share. The warrants are exercisable immediately upon closing of the private placement and have a term of three years.

BrainStorm Expands Pipeline With Initiation of Pre-Clinical Study in Autism
Marketwire - Tue Jun 10, 6:10AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has initiated a study in a mouse model of autism at the Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, under the direction of Professor Daniel Offen. The study will explore the effects of the company's "MSC-NTF" cells on mouse behavior.

BrainStorm Cell Therapeutics Appoints Tony Fiorino, MD, PhD as Chief Executive Officer
Marketwire - Mon Jun 09, 6:30AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has appointed Tony Fiorino, MD, PhD as its new Chief Executive Officer (CEO).

BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
Marketwire - Tue Mar 25, 5:01AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis (ALS), pending FDA and Institutional Review Board approvals. The other two clinical sites slated for the multi-center trial are the University of Massachusetts Memorial (UMass) Hospital and Mayo Clinic. Dana Farber Cancer Institute's Connell and O'Reilly Cell Manipulation Core Facility will manufacture the NurOwn cells for MGH and UMass Hospital.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 438

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 325

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 365

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 280

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 210

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 278

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 261

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 443

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 448

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 349

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

ANSI Electric Vehicles Standards Panel Releases New Report

Updated Category News Views 285

ANSI Electric Vehicles Standards Panel Releases New Report In a significant step towards enhancing the adoption of electric vehicles (EVs) and their infrastructure, the American National Standards Institute (ANSI) has unveiled the May 2025 Gaps Progress Report. This report is integral to understanding the collaborative efforts being made by various stakeholders to bridge...

Continue Reading
Oklahoma Startups Thrive in Catalyst Accelerator Boot Camp

Updated Category News Views 575

Catalyst Accelerator Empowers Startups through Innovative Boot Camp The Catalyst Accelerator is thrilled to unveil a significant opportunity for six emerging tech startups in Oklahoma. This new initiative, the Government Business Boot Camp, is fashioned to equip these talented companies with the insights and tools necessary to succeed in government contracting. In...

Continue Reading
Legal Action Commences for Biogen Inc. (NASDAQ: BIIB) Investors

Updated Category News Views 200

Legal Investigation for Biogen Inc. Stockholders Bragar Eagel & Squire, P.C., a reputable law firm, is currently investigating claims against Biogen Inc. (NASDAQ: BIIB) on behalf of long-term stockholders. This investigation follows the recent filing of a class action complaint aimed at holding the company accountable for alleged misleading statements regarding its...

Continue Reading
Understanding the Urgent Need for Data Governance in AI

Updated Category News Views 133

The Growing Importance of Data Governance in AI As the landscape of business evolves, the adoption of artificial intelligence (AI) in enterprises has surged, leading to significant transformations in operations, development, and knowledge work. However, this rapid integration of AI solutions has brought about new data risks that traditional technologies often overlook....

Continue Reading
Oracle's High Debt Levels Raise Concerns for Investors

Updated Category News Views 797

Oracle’s Debt Concerns Illuminate Financial Landscape In a recent analysis, a leading strategist from J.P. Morgan has drawn attention to the substantial debt levels of Oracle Corp. (NYSE: ORCL). Reporting a staggering 500% debt-to-equity ratio, Oracle’s financial commitments appear considerably higher when compared to other companies in the sector. Analysis from J.P....

Continue Reading